Contact Us


Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45 
Fax 0032 16 50 90 45
This email address is being protected from spambots. You need JavaScript enabled to view it.  

Gentaur Bulgaria

53 Iskar Str. 1191 Kokalyane, Sofia
Tel 0035924682280 
Fax 0035929830072
This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR France
    Gentaur Germany

      GmbH Marienbongard 20
    52062 Aachen Deutschland
    Tel (+49) 0241 56 00 99 68 
    Fax (+49) 0241 56 00 47 88 
    This email address is being protected from spambots. You need JavaScript enabled to view it.

    This email address is being protected from spambots. You need JavaScript enabled to view it.


    Gentaur London

     GENTAUR Ltd. 
    Howard Frank Turnberry House 
    1404-1410 High Road 
    Whetstone London N20 9BH 
    Tel 020 3393 8531 
    Fax 020 8445 9411
    This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Poland

     GENTAUR Poland Sp. z o.o. 

    ul. Grunwaldzka 88/A m.2

    81-771 Sopot, Poland
    Tel  058 710 33 44
    Fax 058 710 33 48 
    This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Nederland

     GENTAUR Nederland BV
    Kuiper 1 
    5521 DG Eersel Nederland
    Tel 0208-080893 
    Fax 0497-517897
    This email address is being protected from spambots. You need JavaScript enabled to view it.

    Gentaur Italy

     GENTAUR SRL IVA IT03841300167

    Piazza Giacomo Matteotti, 6, 24122 Bergamo
    Tel 02 36 00 65 93 
    Fax 02 36 00 65 94
    This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Spain

     GENTAUR Spain
    Tel 0911876558
    This email address is being protected from spambots. You need JavaScript enabled to view it.

    Genprice USA
    Gentaur Serbia

    serbiaSerbia, Macedonia FlagMacedonia, 

    montenegro-flagMontenegro, croatiaCroatia: 
    Tel 0035929830070 
    Fax 0035929830072
    This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Romania

    romGENTAUR Romania

    Tel 0035929830070 
    Fax 0035929830072
    This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Greece

    grGENTAUR Greece 

    Tel 00302111768494 
    Fax 0032 16 50 90 45

    This email address is being protected from spambots. You need JavaScript enabled to view it.

    Other countries

    Other countries
    Luxembourg +35220880274
    Schweiz Züri +41435006251
    Danmark +4569918806
    Österreich +43720880899
    Ceská republika Praha +420246019719
    Ireland Dublin +35316526556
    Norge Oslo +4721031366
    Finland Helsset +358942419041
    Sverige Stockholm +46852503438
    Magyarország Budapest +3619980547




    924151 3-monoclonal-polyclonal-peptide-biological-research-products-knock-out-ratAt the annual conference of the American Academy of Neurology (AAN), which will be held from April 26 to May 3 in Philadelphia, will be presented to the successful outcome of Phase II clinical trial of two brand new compared to existing drugs for the prevention of migraine attacks, according to a press release AAN. Both drugs are used first for the prevention of migraine monoclonal antibody. The creators promise a new era of medicine in preventive therapy for this disease.

    Target against which drugs work, also not previously been involved in order to prevent migraine attacks - monoclonal antibodies block the calcitonin gene-related peptide (CGRP), synthesized by cells of the central and peripheral nervous system neurotransmitter that plays a key role in the transmission of pain.

    During the first tests of medicines, ALD403, 163 patients suffering from migraine attacks from five to 14 days per month or one placebo dose. Over the next six months, the group received the drug was observed 66 percent reduction in the number of attacks per month, compared to 52 percent reduction in the group receiving placebo. In 16 percent of the participants received the drug group attacks were completely absent for three months, which was not observed in the placebo group. Difference in side effects between the groups was observed.

    In trials of another drug, LY2951742, 217 patients suffering from migraine from 4 to 14 days a month, for three months received twice weekly subcutaneous injections of placebo or drug. In the group receiving therapy, there was a 63 percent reduction in seizure frequency per month compared with a 42 percent decline in the placebo group. In patients receiving the drug were noted side effects such as pain at the injection site, pain in the abdomen and upper respiratory tract infection, but in general medicine was found to be safe and well tolerated.

    Although both drugs is still the third phase of clinical trials, according to the representative of the University of California (San Francisco) Godsbi Peter (Peter Goadsby), participated in the creation and testing of both drugs, the results are potentially promising new era in preventive treatment of migraine.

    Migraine affects about 14 percent of the adult population and, according to the global health research people on Earth Global Burden of Disease Survey in 2010, is the seventh of disabling diseases.

    Published in News
    Thursday, 10 April 2014 10:33

    Tobacco plants are struggling with virus

    Tobacco plants are struggling with virusInternational research group led by Professor Chen has developed a new generation of potentially safer and more cost-effective therapies against West Nile virus etc, and other pathogens.

    Scientists applied therapy based on monoclonal antibodies and their derivatives.

    For the purposes of the study monoclonal antibodies are derived from tobacco plants, which is promising to change the image of the plant, which are believed to cause cancer of the lung.

    The antibodies are directed against proteins located on the surface of the virus.

    The main objective of the study is to create innovative, sustainable and affordable therapy that also be a cheap solution to combat the global threat of West Nile virus.

    One approach is the development of therapeutic antibodies that bind to receptors which may help of the monoclonal antibodies to cross into the brain.

    In a new study, the researchers developed a half-dozen new options that could assist in the implementation monoclonal antibodies that can be effectively targeted to the brain and to neutralize the dangerous virus.

    The final results of the study show 90% success in preventing letalnit development in experimental conditions.

    This is the first case of such an effect, leading to the neutralization of the virus.

    Dr. Chen results are motivating the development of plant-based therapy that dramatically reduce the cost of commercial production of monoclonal antibodies.

    The virus is spread by infected mosquitoes and affect the central nervous system.

    Infection can cause serious, life-altering and even fatal disease.

    Until now, however, is not available or effective drug therapy for dealing with infection.

    Published in News
    Monday, 20 January 2014 11:50

    Monoclonal Mouse anti-HSV-2 gC antibody

    Herpes Simplex Virus 1 Glycoprotein C Antibody 3G9-Immunocytochemistry-Immunofluorescence-NB110-57251-img0007

    Specificity: In a simple ELISA, 4955-0308 only reacts with HSV-2 gC antigen. It does not react with gD or any other antigen preparations from HSV-1.


    Catalog Num.: 4955-0308

    Quantity: 0.2 mg

    Target: HSV-2 gC

    Clone: 1073/53

    Host: Mouse

    Applications: ELISA

    Conjugate/Tag/Label: Unconjugated

    Purity: Ammonium sulfate precipitation

    Reactivity: Herpes Simplex Virus

    PDF-IconDatasheet: Monoclonal Mouse anti-HSV-2 gC antibody

    Price: 350 €

    Order Button1


    More: Antibodies

    Published in Promos
    Monday, 07 October 2013 15:15

    New Antibodies from Gentaur

    Gentaur provides a wide range of specialist antibodies, primarily to aid research in the cellular stress, heat shock, ion channel and transporter fields of study. However we also provide antibodies as research tools for Apoptosis, Cell Signaling and Post-translational Modification amongst others.

    If you need help finding the reagent that meets your requirements, please contact us at This email address is being protected from spambots. You need JavaScript enabled to view it.

    HO-1 (Rat) Antibody

    Catalog#: SPC-207D
    Package size: 100ug
    Type: Polyclonal
    Datasheet: SPC 207 Heme oxgenase 1 Heat Shock Protein 32 (HO 1)
    Description: Anti-HO-1 (Rat)

    HSF1 Antibody

    Catalog#: SPC-208D
    Package size: 100ug
    Type: Polyclonal
    Datasheet: SPC 208 Heat Shock Factor 1 (HSF1)
    Description: Anti-HSF1

    LGI1 Antibody

    Catalog#: SMC-461D
    Package size: 100ug
    Type: Monoclonal
    Datasheet: SMC 461 LGI1
    Description: Anti-LGI1

    LRRK2/Dardarin Antibody

    Catalog#: SMC-445D
    Package size: 100ug
    Type: Monoclonal
    Datasheet: SMC 445 LRRK2 Dardarin N3
    Description: Anti-LRRK2/Dardarin

    PEX6 Antibody

    Catalog#: SMC-470D
    Package size: 100ug
    Type: Monoclonal
    Datasheet: SMC 470 PEX6
    Description: Anti-PEX6

    PINK1 Antibody

    Catalog#: SMC-450D
    Package size: 100ug
    Type: Monoclonal
    Datasheet: SMC 450 PINK1
    Description: Anti-PINK1

    Pan-QKI Antibody

    Catalog#: SMC-467D
    Package size: 100ug
    Type: Monoclonal
    Datasheet: SMC 467 Pan QKI
    Description: Anti-Pan-QKI

    SOD1 (UβB) Antibody

    Catalog#: SPC-205D
    Package size: 100ug
    Type: Polyclonal
    Datasheet: SPC 205 SOD1 (UBB) Oxidative Stress
    Description: Anti-SOD1 (UβB)

    SOD1 (EDI) Antibody

    Catalog#: SPC-206D
    Package size: 100ug
    Type: Polyclonal
    Datasheet: SPC 206 SOD1 (EDI) Oxidative Stress
    Description: Anti-SOD1 (EDI)

    TRAP1 Antibody

    Catalog#: SPC-209D
    Package size: 100ug
    Type: Polyclonal
    Datasheet: SPC 209 TRAP1 Heat Shock Protein
    Description: Anti-TRAP1


    Order Button1

    Published in Promos
    Monday, 26 August 2013 17:06

    HIV-1 p24 Antigen ELISA (1x 96 well)

    Virus Core Antigen Detection

    HIV-1 p24 Antigen ELISA 1x 96 well

    - Measures the p24 core protein of HIV-1
    - Quantitation is performed on a standard microplate reader
    - p24 Standard included

    Overview: An anti-HIV p24 monoclonal coating antibody is adsorbed onto a microtiter plate. p24 antigen present in the sample or standard binds to the antibodies adsorbed on the plate; a FITC-conjugated mouse anti-p24 antibody is added and binds to p24 antigen captured by the first antibody.

    Following incubation and wash steps, a HRP-conjugated mouse anti-FITC antibody is added and binds to the FITC conjugated anti-p24. Following unbound HRP-conjugated mouse anti-FITC antibody is removed during a wash step, and substrate solution reactive with HRP is added to the wells.

    A colored product is formed in proportion to the amount of p24 antigen present in the sample. The reaction is terminated by addition of acid and absorbance is measured at 450 nm. A standard curve is prepared from recombinant HIV-1 p24 protein and sample p24 concentration is then determined.

    Storage: Store all kit reagents at 2° - 8°C. DO NOT FREEZE. When stored properly the kit is stable until the date indicated on the box label.

    PDF-IconDownload datasheet

    Price: 486 Euro

    Order Button1

    Published in Top Products

    Product Description

    Mouse monoclonal antibody to K-bZIP of Herpes Virus Type 8. This antibody originates from ascites fluids and is purified by protein G agarose affinity chromatography.

    Catalog No.


    Unit Size

    500 µg


    Mouse IgG



    Protein Concentration

    1 mg/ml (A280)


    Phosphate Buffered Saline (PBS) pH 7.4


    Protein G agarose affinity chromatography

    Functional Activity

    Reactive with SUMOylated and non-SUMOylated species of K-bZIP of Herpes Virus Type 8 in immunofluorescence (IFA) and western blot at 10 µg/ml.

    Shipping & Storage

    This product is supplied frozen on dry ice. Upon receipt, store at -20°C. Avoid multiple freeze-thaw cycles as product degradation may result.


    Order Button1



    More: Monoclonal Antibody

    Published in Promos

    We are currently offering a comprehensive panel of antibodies specific for human Norovirus, including GII.4 2012 Sydney strain.  MAB223P through MAB228P have been tested across a broad range of strains, as reported in the table below.  In addition to being broadly cross reactive to GII.4 genotypes, MAB227P has demonstrated the ability to block ligand binding in surrogate neutralization assays.  MAB228P, developed against GI.1 1968 virus like particles (VLPs), has been shown to recognize additional GI types.  There are currently five known genogroups, of which three cause human disease: GI, GII, and GIV.  According to the CDC, since 2002 GII.4 has been the most common cause of Norovirus outbreaks.


    Order Button1

    Published in Promos
    Wednesday, 03 April 2013 09:55

    Parasitology: Cysticercosis Antigen ELISA

    Apdia beeld hersenscanThe Cysticercosis Antigen (Ag) ELISA (Ref. 650501) is a sandwich Enzyme-Linked ImmunoSorbent Assay based on monoclonal antibodies for the qualitative determination of viable metacestodes (cysticerci) of Taenia spp. in human and porcine serum samples.

    -  Analytical sensitivity: 1 cyst is detectable in certain conditions
    - Incubation times: assay 45 minutes + sample prep <30 minutes
    - Available format: 96T

    Taenia solium cysticercosis is an infection of humans and pigs with metacestode larvae (cysticercus) of Taenia solium. Circulating antigen detection in serum is an important diagnostic method that indicates the presence of viable parasites. The monoclonal antibodies used in this assay are produced against excretory secretory products (ESP) of viable T. saginata cysticerci. The glycoprotein antigens detected by these monoclonal antibodies are present on the tegument and in the excretory secretory products of metacestodes.

    The assay demonstrates the presence of viable cysticerci only, it does not detect degenerated or calcified cysticerci. In this respect, unlike antibody detection, measurement of circulating antigen levels allows differentiation of cysticercosis cases with viable parasites, with antigen levels correlating to the numbers and size of lesions. It can as such also provide a tool for serological monitoring of antiparasitic therapy in human or pigs: antigen levels drop rapidly after successful anthelminthic treatment.

    Porcine cysticercosis

    The assay is genus specific, not species specific. The assay does not allow the differentiation between infections of different Taenia species in pigs. In experimentally infected pigs, circulating antigens were first detected between 2 and 6 weeks post infection and remained present generally throughout an observation period of 6 months, even in pigs carrying only five to eight living cysts. The minimum number of living cysts, that could be detected using the Cysticercosis Ag ELISA, was one.

    Human cysticercosis

    Because T. solium is the only Taenia sp. causing cysticercosis in man, the test is specific. No cross-reactions were observed with sera from patients with other parasitologically and/or serologically confirmed infections. The sensitivity of the assay decreases when the number of viable cysts is low; infections with one viable cyst are often not detectable. Antigen levels are generally higher in extraparenchymal neurocysticercosis (NCC) (particularly subarachnoid NCC) than in intraparenchymal NCC; therefore, high antigen levels should lead one to suspect the presence of extraparenchymal NCC.

    Order Button1

    PDF-IconDownload datasheet


    Published in Promos

    monoclonal antibodyResearchers have discovered a unique monoclonal antibody that can effectively reach inside a cancer cell, a key goal for these important anticancer agents, since most proteins that cause cancer or are associated with cancer are buried inside cancer cells. Scientists from Memorial Sloan-Kettering Cancer Center and Eureka Therapeutics have collaborated to create the new human monoclonal antibody, which targets a protein associated with many types of cancer and is of great interest to cancer researchers.

    Unlike other human therapeutic monoclonal antibodies, which can target only proteins that remain on the outside of cancer cells, the new monoclonal antibody, called ESK1, targets a protein that resides on the inside of the cell. ESK1 is directed at a protein called WT1, which is overexpressed in a range of leukemias and other cancers including myeloma and breast, ovarian, and colorectal cancers. WT1 is a high priority target for cancer drugs because it is an oncogenic protein, meaning that it supports the formation of cancer. In addition, it is found in few healthy cells, so there are less likely to be side effects from drugs that target it. "This is a new approach for attacking WT1, an important cancer target, with an antibody therapy. This is something that was previously not possible," said David A. Scheinberg, MD, PhD, Chair of the Sloan-Kettering Institute's Molecular Pharmacology and Chemistry Program and an inventor of the antibody. "There has not been a way to make small molecule drugs that can inhibit WT1 function. Our research shows that you can use a monoclonal antibody to recognize a cancer-associated protein inside a cell, and it will destroy the cell." 

    The first studies of the antibody are showing promise in preclinical research as a treatment for leukemia as reported March 13, 2013, in Science Translational Medicine. "ESK1 represents a paradigm change for the field of human monoclonal antibody therapeutics," said Cheng Liu, PhD, President and Chief Executive Officer of Eureka Therapeutics. "This research suggests that human antibody therapy is no longer limited to targeting proteins present outside cancer cells, but can now target proteins within the cancer cell itself."

    ESK1 was engineered to mimic the functions of a T cell receptor, a key component of the immune system. T cells have a receptor system that is designed to recognize proteins that are inside the cell. As proteins inside the cell get broken down as part of regular cellular processes, molecules known as HLA molecules carry fragments of those proteins -- known as peptides -- to the surface. When T cells recognize certain peptides as abnormal, the T cell kills the diseased cell. In the current study, the investigators showed that ESK1 alone was able to recognize WT1 peptides and kill cancer cells in the test tube and also in mouse models for two different types of human leukemia. "We were surprised that the antibody worked so well on its own," said Dr. Scheinberg, senior author of the paper. "We had originally expected that we might need to use the antibody as a carrier to deliver a drug or a radioactive therapy to kill the cancer cells, but this was not necessary."

    Additional studies must be done in the laboratory before ESK1 is ready to be tested in patients. But the monoclonal antibody was engineered to be fully human, which should speed the time it takes to move the drug into the clinic. Researchers expect that the first clinical trials, for leukemia, could begin in about a year.

    The antibody was developed under a collaborative effort between Memorial Sloan-Kettering and Eureka, which have jointly filed for patent protection. This work was supported by grants from the Leukemia and Lymphoma Society, the National Cancer Institute, the Sloan-Kettering Institute's Experimental Therapeutics Center and Technology Development Fund, the Commonwealth Foundation for Cancer Research, the Tudor and Glades Foundations, the Merker Fund, the Lymphoma Foundation, and the Mesothelioma Applied Research Foundation.

    Published in News
    Wednesday, 06 February 2013 14:34

    PSA ELISA Kit 96t


    Catalog number : 2125-96T
    Availability: Yes

    Details: This kit is a solid phase-phase sandwich enzyme linked immuno sorbent assay (ELISA). Samples, including standards of known target protein concentrations and unknowns are pipetted into these wells. During the first incubation, the target protein antigen and a biotinylated monoclonal antibody specific for target protein are simultaneously incubated. After washing, the enzyme (streptavidin-peroxydase) is added. After incubation and washing to remove the entire unbound enzyme, a substrate solution which is acting on the bound enzyme is added to induce a colored reaction product. The intensity of this colored product is directly proportional to the concentration of target protein present in the samples.


     Price: 173 EUR

    Order Button1

    Published in Top Products